When to use supportive treatment, lenalidomide (revlimid), and bone marrow transplantation in the treatment of myelodysplastic syndromes (MDS)?

Treatment Selection in Myelodysplastic Syndromes

Risk Stratification First

All treatment decisions in MDS must begin with IPSS-R risk stratification, which divides patients into lower-risk (very low, low, intermediate) and higher-risk (high, very high) categories—each requiring fundamentally different therapeutic goals and approaches. 1, 2

• IPSS-R scoring incorporates cytogenetic risk, bone marrow blast percentage, hemoglobin, platelet count, and absolute neutrophil count 2
• Molecular analysis adds prognostic value, particularly TP53 mutations in del(5q) MDS and SF3B1 mutations in patients with <5% blasts 1, 2
• Lower-risk MDS treatment aims for hematologic improvement and quality of life 1, 2
• Higher-risk MDS treatment aims to modify disease course and prolong survival 1, 2

---

When to Use Supportive Treatment

Supportive care is indicated for all MDS patients at some point, but serves as the primary treatment strategy for three specific groups: very frail patients regardless of risk category, lower-risk patients without significant cytopenias, and patients who have failed disease-modifying therapies. 1

Specific Indications for Supportive Care as Primary Treatment:

• Very frail patients with higher-risk MDS who cannot tolerate azacitidine or transplant 1
• Lower-risk MDS patients without transfusion dependence or severe cytopenias who can be observed 1, 3
• Patients failing all disease-modifying therapies in both lower and higher-risk categories 1

Components of Supportive Care:

• RBC transfusions maintaining hemoglobin ≥8 g/dL, or 9-10 g/dL with comorbidities worsened by anemia 1, 2
• Transfuse sufficient RBC concentrates to increase hemoglobin >10 g/dL to limit chronic anemia effects on quality of life 1, 2
• Platelet transfusions for severe thrombocytopenia or bleeding (not routinely prophylactic) 1
• G-CSF or GM-CSF for neutropenic patients with recurrent infections (not prophylactic) 1
• Psychosocial support and patient support group contacts 1, 2
• Iron chelation consideration for transfusion-dependent patients with iron overload 1

---

When to Use Lenalidomide

Lenalidomide is the treatment of choice specifically for lower-risk MDS patients with del(5q) cytogenetic abnormality who have transfusion-dependent anemia, achieving 60-67% transfusion independence rates. 2, 4, 5

Specific Criteria for Lenalidomide:

• Lower-risk MDS (IPSS low/INT-1 or WPSS very low/low/intermediate) 1, 2
• Del(5q) cytogenetic abnormality present 2, 4, 5
• Transfusion-dependent anemia requiring treatment 2, 5
• Can be used after ESA failure or as first-line in del(5q) patients 1, 3

Dosing and Monitoring:

• Standard dose: 10 mg daily for 21 out of 28 days or continuous daily dosing 4
• Response assessment at 2-4 months 4
• Median time to response: 4.6 weeks 4
• Dose reduction to 5 mg daily (not interval extension) for cytopenias 4
• CBC weekly for first 8 weeks, then monthly 4

Important Caveat:

• Lenalidomide has limited efficacy in non-del(5q) MDS and is not standard treatment for this population 5
• For higher-risk MDS, lenalidomide is investigational and not standard therapy 6

---

When to Use Bone Marrow Transplantation

Allogeneic stem cell transplantation is the only potentially curative treatment for MDS and should be performed soon after diagnosis in fit patients ≤70 years with higher-risk disease (IPSS INT-2/high or WPSS high/very high) who have an available donor. 1, 2

Immediate Transplant Candidates (Proceed Soon After Diagnosis):

• Age ≤60-70 years with adequate performance status 1
• Higher-risk MDS (IPSS INT-2/high or WPSS high/very high) 1, 2
• Available HLA-matched sibling or unrelated donor 1
• No major comorbidities limiting transplant eligibility 1
• Markov decision analysis shows IPSS INT-2 and high-risk patients aged ≤60 years have highest life expectancy with early transplant 1

Delayed Transplant Strategy:

• IPSS low-risk MDS: delay transplant until disease progression for best life expectancy 1
• IPSS INT-1 risk: individualize timing based on platelet/neutrophil counts and other factors 1
• Lower-risk MDS (WPSS very low/low/intermediate): consider transplant closer to transformation 1, 7

Conditioning Regimen Selection:

• High-dose conditioning: younger patients (typically <55-60 years) regardless of blast burden 1
• Reduced-intensity conditioning (RIC): patients >55-60 years, particularly with <10% marrow blasts 1
• Pre-transplant debulking with azacitidine or chemotherapy if blast count is high 1

Transplant Outcomes by Risk:

• WPSS lower-risk: 80% 5-year survival post-transplant 1
• WPSS intermediate-risk: 65% 5-year survival 1
• WPSS high-risk: 40% 5-year survival 1
• WPSS very high-risk: 15% 5-year survival 1

---

Treatment Algorithm for Higher-Risk MDS

Fit Patients ≤70 Years with Donor:

Proceed to allogeneic stem cell transplantation 1, 2

• May precede with 2-6 cycles of azacitidine to reduce blasts or for logistical reasons 1
• AML-like chemotherapy can be considered for fit patients <70 years without unfavorable cytogenetics and >10% marrow blasts as bridge to transplant 1

Patients >70 Years or Without Donor:

Azacitidine is the first-line reference treatment 1, 2

• Dose: 75 mg/m²/day subcutaneously for 7 consecutive days every 28 days 1, 2
• Alternative "5-2-2" regimens are acceptable 1
• Minimum 6 cycles required before assessing efficacy 1, 2
• Decitabine is an alternative hypomethylating agent 1

Very Frail Patients:

Supportive care only 1

• RBC transfusions, antibiotics, growth factors as needed 1
• Consider clinical trials if available 1

---

Treatment Algorithm for Lower-Risk MDS

Anemia Management:

First-line: Erythropoiesis-stimulating agents (ESAs) if serum EPO <500 U/L and requiring <2 RBC units/month 2, 3

Second-line options after ESA failure:

• Del(5q) present: Lenalidomide 10 mg daily for 21/28 days 2, 4
• MDS-RS or SF3B1 mutation: Luspatercept (achieves 63% erythroid response, 38% transfusion independence) 2
• Hypoplastic MDS, age ≤60, HLA-DR15+, or PNH clone: Immunosuppressive therapy (ATG or cyclosporine) 1
• Other cases: Consider azacitidine, decitabine, or clinical trial 1, 3

Thrombocytopenia Management:

• Thrombopoietin receptor agonists (romiplostim, eltrombopag) in clinical trials 1
• ATG or hypomethylating agents (35-40% platelet response) 1

Neutropenia Management:

• G-CSF or GM-CSF for recurrent infections (not prophylactic) 1
• Immunosuppressive therapy for hypoplastic MDS 1

---

Critical Pitfalls to Avoid

• Do not stop azacitidine before 6 cycles in higher-risk MDS—most patients only respond after several courses 1, 2
• Do not use lenalidomide in non-del(5q) lower-risk MDS as standard therapy—efficacy is limited 5
• Do not delay transplant in IPSS INT-2/high-risk patients ≤60 years—early transplant maximizes life expectancy 1
• Do not use prophylactic G-CSF or antibiotics for neutropenia—no survival impact demonstrated 1
• Do not undertransfuse—maintain hemoglobin targets of 8-10 g/dL to optimize quality of life 1, 2